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The hexanucleotide repeat expansion in C9orf72 is a common cause of amyotrophic lateral sclerosis/
frontotemporal dementia and also rarely found in other psychiatric and neurodegenerative conditions.
Alleles with >30 repeats are often considered an expansion, but the pathogenic repeat length threshold
is still unclear. It is also unclear whether intermediate repeat length alleles (often deﬁned either as 7e30
or 20e30 repeats) have clinically signiﬁcant effects. We determined the C9orf72 repeat length distri-
bution in 3142 older Finns (aged 60e104 years). The longest nonexpanded allele was 45 repeats. We
found 7e45 repeats in 1036/3142 (33%) individuals, 20e45 repeats in 56/3142 (1.8%), 30e45 repeats in
12/3142 (0.38%), and expansion (>45 repeats) in 6/3142 (0.19%). There was no apparent clustering of
neurodegenerative or psychiatric diseases in individuals with 30e45 repeats indicating that 30e45 re-
peats are not pathogenic. None of the 6 expansion carriers had a diagnosis of amyotrophic lateral
sclerosis/frontotemporal dementia but 4 had a diagnosis of a neurodegenerative or psychiatric disease.
Intermediate length alleles (categorized as 7e45 and 20e45 repeats) did not associate with Alzheimer’s
disease or cognitive impairment.
 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
C9orf72 hexanucleotide repeat expansion is a major cause of
sporadic and familial amyotrophic lateral sclerosis (ALS) and fron-
totemporal dementia (FTD) (DeJesus-Hernandez et al., 2011;
Renton et al., 2011), and it is particularly common in Finland
(Majounie et al., 2012). Expansions can span up to several 1000
repeats, but the minimum length of pathogenic expansion is not
known. Knowledge on the distribution of repeat lengths in thei, Research Programs Unit,
nd. Tel.: þ358 50 522 3563;
).
er Inc. This is an open access articgeneral population could help gain a better understanding of the
threshold for pathogenicity. Perhaps the most widely used
threshold for expansion is 30, deﬁned in one of the original studies
describing the C9orf72 repeat (Renton et al., 2011). Determining a
threshold for expansion is complicated by the difﬁculty of reliably
determining repeat lengths, and thresholds reﬂect more the limi-
tation of used methods than actual alteration in biologic function.
Southern blot is considered to be the golden standard of repeat
length estimation but because of its high demand of good quality
DNA, cost, and work load, often other methods such as repeat-
primed PCR (RP-PCR) are used.
Besides genuine expansions, “intermediate length” alleles (deﬁned
often as 7e30 or 20e30 repeats) have also been hypothesized tole under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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intermediate alleles showed decreased C9orf72 promoter activity as
compared to short repeat alleles (Gijselinck et al., 2016). Moreover,
adverse effects have been observed in a ﬂy model with 30 repeats
(Zhang et al., 2015), although the relevance ofﬂy physiology to human
pathophysiology in this context is unsure. As with expansion, the
threshold for intermediate length repeats also varies in studies but
allele length7has been shown to associatewith theC9orf72 founder
haplotype in the European population (van der Zee et al., 2013). A
recent review(NgandTan, 2017) summarized thatmost studiesdonot
ﬁnd association between intermediate length alleles and a variety of
neurodegenerative diseases but intermediate length alleles might be
associated with psychiatric symptoms. Most studies on intermediate
length alleles focus on ALS/FTD spectrumbut only fewon Alzheimer’s
disease (AD) (Cacace et al., 2013; Harms et al., 2013; Jiao et al., 2013;
Kohli et al., 2013; Xi et al., 2012).
In this study, we present C9orf72 hexanucleotide repeat length
distribution in 3142 Finns and study the association of intermediate
repeat alleles with AD and cognitive impairment.
2. Methods
2.1. Cohorts
We studied the C9orf72 hexanucleotide repeat length in 3161
individuals from 4 population-derived cohorts from the Helsinki
region in Southern Finland. These were the Vantaa 85þ study
(Tanskanen et al., 2017) (n¼ 469), Helsinki Birth cohort study (Barker
et al., 2005; Eriksson et al., 2006; Kajantie et al., 2012; Lahti et al.,
2014; Yliharsila et al., 2007) (n ¼ 1651), Helsinki Businessmen
study (Strandberg et al., 2016) (n ¼ 666), and DEBATE study
(Uusvaara et al., 2013) (n ¼ 375). We have previously used the same
cohorts to study the association of TYROPB deletion and cognitive
impairment (Kaivola et al., 2018). Information on AD, other dementia
diagnoses, mini mental state examination (MMSE) scores, or lack of
dementia was assessed from clinical records, death certiﬁcates, reg-
istry information, or questionnaires. The source of information varied
between cohorts. More detailed cohort descriptions and information
on assessment of dementia are provided in the Supplementary
Methods.
We studied the effect of intermediate repeat alleles in 3 settings:
(1) individuals with AD versus no AD; (2) individuals with cognitive
impairment (MMSE score24) versus individuals with no cognitive
impairment (MMSE score >24), and (3) individuals with cognitive
impairment or any diagnosis of dementia versus nondemented
controls. All controls were 75 years. Repeat lengths 7e45 and
20e45 were used as the deﬁnition of intermediate length alleles.
2.2. Genetic analyses
We determined repeat lengths with RP-PCR as previously
described (Renton et al., 2011) with minor changes to the protocol
(Supplementarymethods). Because it may be difﬁcult to distinguish
between an expansion and a long repeat in RP-PCR, we conﬁrmed
alleles with repeat length 20 and all putative expansions with
over-the-repeat PCR. Samples with more than 30 repeats and the
typical sawtooth pattern in RP-PCR, which only produced the
smaller amplicon in over-the-repeat PCR, were categorized as ex-
pansions (Supplementary Fig. 1).
The smallest allele is here denoted as 2e3 repeats because 2 and 3
repeat alleles cannot be distinguished by RP-PCR. RP-PCR resultsmay
be inaccurate in distinguishing heterozygosity and homozygosity in
certain allele combinations (especially 2e3/5 from 5/5 and 5/8 from
8/8). This can slightly increase the proportion of heterozygotes at the
expense of homozygotes. Considering this uncertainty, we did notanalyze cognitivemeasures separately in individuals homozygous for
the intermediate alleles. There were no samples homozygous for the
20e45 repeat alleles in our cohorts. APOE was genotyped as previ-
ously described (Myllykangas et al., 1999).
2.3. Statistics
We used logistic regression to test for association between in-
termediate repeats in all 3 settings and used APOE ε4 carriership,
age, and sex as covariates. We applied Bonferroni correction to take
account of multiple test settings and set the statistical signiﬁcance
to p¼ 0.05/3 ¼ 0.017. We used Kruskal-Wallis H test to determine if
repeat length distributions differed between our 4 cohorts. All an-
alyses were conducted with IBM SPSS statistics v.24 (IBM Corp.
Released, 2016. IBM SPSS Statistics for Windows, Version 24.0. IBM
Corp., Armonk, NY, USA).
Assuming AD prevalence of 10% in Finnish individuals aged over
75 years (Rahkonen et al., 2003), intermediate allele (7 repeats)
frequency of 17% based on our initial results, case-control ratio of
1:4, type 1 error rate 0.05 and relative risk of 1.5 with dominant
effect, 201 cases were required for 80% power (Purcell et al., 2003)
(Genetic power calculator, http://zzz.bwh.harvard.edu/gpc/
accessed 4.6.2018). From the 4 cohorts, we identiﬁed 226 in-
dividuals with AD, 432withMMSE24, and 613with any diagnosis
of dementia or cognitive impairment.
2.4. Ethics
The study was approved by the Coordinating Ethics Committee
of the Helsinki University Central Hospital. The Vantaa 85þ study
was also approved by the Ethics Committee of the Health Centre of
the City of Vantaa.
3. Results
3.1. Repeat length distribution
We successfully determined repeat lengths in 3142/3161 (99.4%)
individuals. There was no statistically signiﬁcant difference in the
repeat length distributions between cohorts [H (3) ¼ 2.129,
p ¼ 0.55]. Repeat length distribution of all alleles is shown in Fig. 1.
The repeat length distribution showed peaks in repeat numbers
2e3, 5, 8, and 10. The longest nonexpanded allele we could char-
acterize with repeat-primed PCR and amplify with over-the-repeat
PCR was 45 repeats. The longer allele was in the range of 7e45
repeats in 1036/3142 (33%) individuals, 20e45 in 56/3142 (1.8%),
30e45 in 12/3142 (0.38%), and expansion (>45 repeats) in 6/3142
(0.19%). All expansion carriers were from the largest (HBCS) cohort.
Interestingly, repeat lengths 20 were more common in
Finland than reported elsewhere in previous large studies. To
compare the frequency of 20 repeat lengths, we searched
PUBMED for large population based (>1000 individuals) and case-
control studies (>1000 controls) with C9orf72 repeat length dis-
tribution available. Besides the original articles describing the
repeat, we identiﬁed 9 articles (Beck et al., 2013, Cacace et al., 2013,
Fahey et al., 2014, He et al., 2015, Kohli et al., 2013, Nuytemans
et al., 2013, Rutherford et al., 2012, Theuns et al., 2014, van der
Zee et al., 2013) but only 4 had enough detailed information on
20 repeats for comparison. In these 4 studies, the prevalence of
20 repeats was signiﬁcantly lower than in Finland (all allelic
frequencies <0.52% and all p < 0.019, Fisher’s exact test) (Table 1).
Of the 9 studies, only 2 found expansion carriers in their control
groups with carrier frequency of 1/5748 (p¼ 0.0095 vs. our Finnish
sample, Fisher’s exact test) (Theuns et al., 2014) and 11/7579
(p ¼ 0.60 vs. FIN) (Beck et al., 2013).
Fig. 1. Repeat length distribution of all alleles in 3142 Finns. “Exp” denotes expansion.
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cognitive impairment
Number of individuals in each cohort with or without AD/
cognitive impairment is shown in Supplementary Table 1.
3.2.1. Alzheimer’s disease
We identiﬁed226 individualswithAD (68e97 years,mean age 86,
58% female,33%carried7e45repeats,1.3%carried20e45repeats)and
893 controls (aged 75e101, mean age 83, 58% female, 33% carried
7e45repeats,1.3% carried20e45repeats). Intermediate repeat length
alleles did not associatewith ADwhen intermediate repeat threshold
was 7 (p ¼ 0.90) or 20 (p ¼ 0.96). Age (p ¼ 3.8  109, odds ratio
[OR] 1.07, 95% conﬁdence interval [CI] 1.05e1.10) and APOE ε4 carri-
ership (p ¼ 5.5  1010, OR 2.69, CI 1.97e3.68) were statistically
signiﬁcantly associated with AD but sex was not (p ¼ 0.45).
3.2.2. MMSE scores
When individuals were divided based only on MMSE score into
cases (MMSE score 24, n ¼ 432, aged 61e99, mean age 85, 75%
female, 27% carried 7e45 repeats, 1.6% carried 20e45 repeats) and
controls (MMSE score 25, n ¼ 719, aged 75e98, mean age 80, 38%Table 1
Comparison of frequency of 20 repeats and expansions in population based datasets or
Population Number of
individuals




Finnish 3142 56 0.89
British 1958 birth cohort 7577 64a 0.42
Irish 1234 10 0.41
European/Asian/North
American/Australian
5886 61 (17 repeats) 0.52
North American 1444 11 0.38
a Written personal communication from Professor Mead.female, 33% carried 7e45 repeats, 1.3% carried 20e45 repeats),
therewas a nominally signiﬁcant association between 7e45 repeats
and better cognition (p ¼ 0.025, OR 0.71 for cognitive impairment,
CI 0.53e0.96), but the association did not remain statistically sig-
niﬁcant after Bonferroni correction. This association disappeared
when repeat length 20 was used as threshold for intermediate
repeat allele (20e45 repeats, p ¼ 0.72). Age (p ¼ 5.0  1020, OR 1.1,
CI 1.1e1.2), female sex (9.8  1014, OR 3.1, CI 2.3e4.1), and APOE ε4
carriership (p ¼ 0.00078, OR 1.7, CI 1.2e2.2) associated signiﬁcantly
with cognitive impairment.
3.2.3. Any diagnosis of dementia or cognitive impairment
We identiﬁed 613 cases (aged 62e101, mean age 86, 65% female,
29% carried 7e45 repeats and 1.3% carried 20e45 repeats) and 1115
controls (aged 75e101, mean age 83, 37% female, 34% carried 7e45
repeats and 1.5% carried 20e45 repeats). There was a nominally
signiﬁcant association between intermediate repeat lengths and
protection from dementia or cognitive impairment (p ¼ 0.032, OR
0.78, CI 0.62e0.98), but this result was not statistically signiﬁcant
after Bonferroni correction, and again, the associationwas lost when
intermediate repeat threshold 20 was used (20e45 repeats,









0.000051 11 (Beck et al., 2013)
0.019 0 (Fahey et al.,
2014)
0.0045 1 (Theuns et al.,
2014)
0.0078 0 (Rutherford et al.,
2012)
Table 2
Summary of individuals with 30 repeats





1 Female 91 2/30 MMSE score 26b
2 Male 70 2/31 MMSE score 29b
3 Female 72 2/31 No dementia diagnosesb
4 Male 85 5/31 MMSE score 28b
5 Male 70 2/32 MMSE score 30b
6 Male 81 2/34 MMSE score 29b
7 Female 89 5/36 MMSE score 21b
8 Male 71 2/40 MMSE score 30/No dementia or psychiatric diagnoses
9 Male 72 2/43 No dementia or psychiatric diagnoses
10 Female 77 2/45 MMSE score 29/No dementia or psychiatric diagnoses
11 Male 74 2/45 MMSE score 29/No dementia or psychiatric diagnoses
12 Female 73 8/45 MMSE score 29/No dementia or psychiatric diagnoses
13 Male 79 2/expansion G20 (Parkinson disease, ICD-10), No psychiatric diagnoses.
14 Female 60a 2/expansion 300.40 (depressive neurosis, ICD-8), 300.88 (other neurosis,
ICD-8). No dementia diagnoses.
15 Female 71 2/expansion G31.0 (local brain atrophy, ICD-10). No psychiatric diagnoses.
16 Male 68a 5/expansion No dementia or psychiatric diagnoses
17 Female 71 6/expansion No dementia or psychiatric diagnoses
18 Female 74 8/expansion 291.20 (Alcoholic psychosis, ICD-8). No dementia diagnoses.
a Age of death, cause of death coronary artery disease.
b Psychiatric diagnoses were not available. RP-PCR chromatograms are provided in Supplementary Fig. 2.
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(p ¼ 4.0  107, OR 1.8, CI 1.4e2.2) associated signiﬁcantly with
dementia or cognitive impairment.
3.2.4. Neurodegenerative and psychiatric diagnoses
We did not ﬁnd any evident clustering of neurodegenerative or
psychiatric disease in the 12 (0.38%) individuals with 30e45 repeats
(Table 2). There were 6 (0.19%) expansion carriers and none had
diagnosis of ALS or FTD; 2 had died at ages of 60 and 68 years
because of coronary artery disease. Of the 4 living individuals (aged
71e79 years), one had been diagnosedwith Parkinson disease (G20,
ICD-10) and another had a diagnosis of local brain atrophy (G31.0,
ICD-10). A third had been diagnosed with “other alcoholic halluci-
nosis” (291.20, ICD-8) and a fourth with depressive neurosis and
other neurosis (300.40 and 300.88, ICD-8). A summary of carriers of
30e45 repeats and expansions is shown in Table 2.
4. Discussion
The C9orf72 hexanucleotide repeat expansion is a major cause of
ALS/FTD; however, what repeat lengths are pathogenic is still un-
clear. Our data on 3142 older individuals show that 30e45 repeats
are found in 0.38% (1 per 262) individuals, and they did not have
any apparent clustering of neurodegenerative or psychiatric dis-
ease. Our data suggest that 30e45 repeat alleles should not be
considered unequivocally pathogenic and other risk factors than
the C9orf72 expansion should be considered in patients with these
alleles. The smallest expansions that segregate with combinations
of ALS, FTD-ALS, and “FTLD or dementia” are reportedly ca. 55e100
repeats as measured by Southern blot (Gijselinck et al., 2016).
However, an individual with 70 repeats without neurodegeneration
at the age of 90 years has been reported (McGoldrick et al., 2018).
More data are still needed for more precise estimation of the
pathological threshold, which may actually turn out as a “gray
zone” where disease penetrance is dependent on modulating
cofactors.
Our data are in line with previous studies indicating a lack of
major association between intermediate repeats and AD. Some-
what surprisingly, there was a nominally signiﬁcant association
between 7e45 repeat length alleles and better cognition. This as-
sociation was not statistically signiﬁcant in any of the individual
cohorts and was only seen in the pooled data set. This can be aspurious association, but nevertheless, it supports the hypothesis
that 7 repeat alleles do not predispose to cognitive impairment or
dementia. Across all our cohorts, therewas heterogeneity in sex and
age distributions, variation in socioeconomic status, and educa-
tional history (one cohort consisted solely of men with high so-
cioeconomic status), and there was no uniform way of deﬁning
cognition and dementia status, and this information was collected
from several sources. Despite these limitations, we found a clear
association between APOE ε4 genotype and AD (p ¼ 5.5  1010, OR
2.69), cognitive impairment (p ¼ 0.00078, OR 1.7), and overall de-
mentia status (p¼ 4.0  107, OR 1.8), which argues against a major
bias in our deﬁnition of dementia. Furthermore, the Finnish
national registers have been found to identify dementia cases
accurately (Solomon et al., 2014).
None of the 6 expansion carriers we identiﬁed had a diagnosis of
ALS or FTD but 4 had a diagnosis of a neurodegenerative or psy-
chiatric disease. Two had died of coronary heart disease before the
age of 70 years and others were under 80 years. Therefore, it is
possible that some expansion carriers could have developed or may
develop ALS/FTD in their later years.
Previous reports have shown that C9orf72 expansion is espe-
cially common cause of ALS/FTD in Finland (Majounie et al., 2012).
In the present study, the expansion frequency in older Finns (me-
dian age 77) was only slightly higher than in the UK 1958 birth
cohort. However, this UK populationwas considerably younger (age
ca. 54e55 years during publication in 2013) than our Finnish
sample. The penetrance of the C9orf72 expansion is known to be
strongly age related; nearly complete penetrance was observed by
83 years in a cohort of 1147 ALS and FTD cases. The median age of
onset varied somewhat with phenotype but was estimated to be
around 58 years (Murphy et al., 2017). Therefore, it can be expected
that the expansion frequency in the UK cohort will markedly
decrease by time. In line with age-related penetrance, the expan-
sions were unequally distributed in our cohorts; all Finnish
expansion carriers were from the HBCS cohort, whose participants
were the youngest of the 4 cohorts (born 1934e1944, and registry
information available up till December 31 of 2013, Supplementary
methods). If we restrict the analysis to this cohort only, expansion
prevalence would be 6/1644 (0.36% or 1 in 274) in Finland.
Interestingly, we found that nonexpanded repeat lengths 20
are roughly twice as common in Finland than in other reported
populations (Table 1). This ﬁnding may have a connection with the
K. Kaivola et al. / Neurobiology of Aging 84 (2019) 242.e7e242.e12242.e11high frequency of C9orf72 expansion in Finland and raises the
questionwhether the20 repeat alleles could be prone to germline
instability and expansion in the offspring. In this scenario, the larger
intermediate alleles would form a pool fromwhich new expansions
can be derived, a mechanism shown in families with sporadic
Huntington’s disease and in Huntington’s disease CAG repeat
knock-in mice (Goldberg et al., 1993; Myers et al., 1993; Wheeler
et al., 1999). Somatic instability (mosaicism) of the expansion has
been previously demonstrated (Dols-Icardo et al., 2014; Fratta et al.,
2015) and at least one family has been described, in which an un-
affected 90-year-old father had a 70-repeat allele in blood (pre-
mutation), which was transmitted to 4 offspring, who all had
expansion in blood DNA (McGoldrick et al., 2018). Whether the
expansion was present in the father’s sperm could not be tested.
However, mosaicism with large expansions was demonstrated in
other tissues; therefore, it is likely that the expansion was present
in sperm. As more than half of the Finnish patients with ALS with
the C9orf72 expansion are sporadic (Majounie et al., 2012) (Laak-
sovirta et al. unpublished data), the spectrum of premutations
warrants further research by genotyping sporadic C9orf72 ALS
cases’ parents when possible. Another approach would be to ge-
notype paired DNA samples from blood and gametes (Martorell
et al., 2004), especially in carriers of the longer alleles.
Disclosure
Bryan J. Traynor and Pentti J. Tienari hold patent on C9orf72 in
diagnostics and treatment of ALS/FTD. The other authors have no
actual or potential conﬂict of interest.
Acknowledgements
KK was funded by the Finnish Cultural Foundation and the UH
Faculty of Medicine MD/PhD program. PJT has been supported by
grants from the Sigrid Juselius Foundation and Helsinki University
Hospital. This work was funded in part by the Intramural Research
Program of the National Institute on Aging, National Institutes of
Health (Z01-AG000949). LM has received funding from the Acad-
emy of Finland (grant number 294817).
The Helsinki Birth cohort study has been funded by The Acad-
emy of Finland, the Finnish Diabetes Research society, Folkhälsan
Research Foundation, Novo Nordisk Foundation, Finska Läkar-
esällskapet, Signe and Ane Gyllenberg Foundation, University of
Helsinki, Ahokas Foundation, Juho Vainio Foundation, and Helsinki
University Hospital.
The Helsinki Businessmen study has been funded by VTR-
funding of the HUS/Helsinki University Hospital (TYH 2014245;
2015211, Sisu) and the Academy of Finland (grant number 311492).
The authors are grateful to Professor Simon Mead (National Prion
Clinic, MRC Prion Unit at the University College London) for sharing
detailed C9orf72 allele distribution in the UK 1958 birth cohort.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.neurobiolaging.2019.
02.026.
References
Barker, D.J., Osmond, C., Forsen, T.J., Kajantie, E., Eriksson, J.G., 2005. Trajectories of
growth among children who have coronary events as adults. N. Engl. J. Med.
353, 1802e1809.
Beck, J., Poulter, M., Hensman, D., Rohrer, J.D., Mahoney, C.J., Adamson, G.,
Campbell, T., Uphill, J., Borg, A., Fratta, P., Orrell, R.W., Malaspina, A., Rowe, J.,
Brown, J., Hodges, J., Sidle, K., Polke, J.M., Houlden, H., Schott, J.M., Fox, N.C.,Rossor, M.N., Tabrizi, S.J., Isaacs, A.M., Hardy, J., Warren, J.D., Collinge, J., Mead, S.,
2013. Large C9orf72 hexanucleotide repeat expansions are seen in multiple
neurodegenerative syndromes and are more frequent than expected in the UK
population. Am. J. Hum. Genet. 92, 345e353.
Cacace, R., Van Cauwenberghe, C., Bettens, K., Gijselinck, I., van der Zee, J.,
Engelborghs, S., Vandenbulcke, M., Van Dongen, J., Baumer, V., Dillen, L.,
Mattheijssens, M., Peeters, K., Cruts, M., Vandenberghe, R., De Deyn, P.P., Van
Broeckhoven, C., Sleegers, K., 2013. C9orf72 G4C2 repeat expansions in Alz-
heimer’s disease and mild cognitive impairment. Neurobiol. Aging. 34,
1712.e1e1712.e7.
DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M.,
Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J., Kouri, N.,
Wojtas, A., Sengdy, P., Hsiung, G.Y., Karydas, A., Seeley, W.W., Josephs, K.A.,
Coppola, G., Geschwind, D.H., Wszolek, Z.K., Feldman, H., Knopman, D.S.,
Petersen, R.C., Miller, B.L., Dickson, D.W., Boylan, K.B., Graff-Radford, N.R.,
Rademakers, R., 2011. Expanded GGGGCC hexanucleotide repeat in noncoding
region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72,
245e256.
Dols-Icardo, O., Garcia-Redondo, A., Rojas-Garcia, R., Sanchez-Valle, R., Noguera, A.,
Gomez-Tortosa, E., Pastor, P., Hernandez, I., Esteban-Perez, J., Suarez-Calvet, M.,
Anton-Aguirre, S., Amer, G., Ortega-Cubero, S., Blesa, R., Fortea, J., Alcolea, D.,
Capdevila, A., Antonell, A., Llado, A., Munoz-Blanco, J.L., Mora, J.S., Galan-
Davila, L., Rodriguez De Rivera, F.J., Lleo, A., Clarimon, J., 2014. Characterization
of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and
frontotemporal dementia. Hum. Mol. Genet. 23, 749e754.
Eriksson, J.G., Osmond, C., Kajantie, E., Forsen, T.J., Barker, D.J., 2006. Patterns of
growth among children who later develop type 2 diabetes or its risk factors.
Diabetologia 49, 2853e2858.
Fahey, C., Byrne, S., McLaughlin, R., Kenna, K., Shatunov, A., Donohoe, G., Gill, M., Al-
Chalabi, A., Bradley, D.G., Hardiman, O., Corvin, A.P., Morris, D.W., 2014. Analysis
of the hexanucleotide repeat expansion and founder haplotype at C9ORF72 in
an Irish psychosis case-control sample. Neurobiol. Aging. 35, 1510.e1e1510.e5.
Fratta, P., Polke, J.M., Newcombe, J., Mizielinska, S., Lashley, T., Poulter, M., Beck, J.,
Preza, E., Devoy, A., Sidle, K., Howard, R., Malaspina, A., Orrell, R.W., Clarke, J.,
Lu, C.H., Mok, K., Collins, T., Shoaii, M., Nanji, T., Wray, S., Adamson, G.,
Pittman, A., Renton, A.E., Traynor, B.J., Sweeney, M.G., Revesz, T., Houlden, H.,
Mead, S., Isaacs, A.M., Fisher, E.M., 2015. Screening a UK amyotrophic lateral
sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion.
Neurobiol. Aging. 36, 546.e1e546.e7.
Gijselinck, I., Van Mossevelde, S., van der Zee, J., Sieben, A., Engelborghs, S., De
Bleecker, J., Ivanoiu, A., Deryck, O., Edbauer, D., Zhang, M., Heeman, B.,
Baumer, V., Van den Broeck, M., Mattheijssens, M., Peeters, K., Rogaeva, E., De
Jonghe, P., Cras, P., Martin, J.J., de Deyn, P.P., Cruts, M., Van Broeckhoven, C., 2016.
The C9orf72 repeat size correlates with onset age of disease, DNA methylation
and transcriptional downregulation of the promoter. Mol. Psychiatry. 21,
1112e1124.
Goldberg, Y.P., Kremer, B., Andrew, S.E., Theilmann, J., Graham, R.K., Squitieri, F.,
Telenius, H., Adam, S., Sajoo, A., Starr, E., 1993. Molecular analysis of new mu-
tations for Huntington’s disease: intermediate alleles and sex of origin effects.
Nat. Genet. 5, 174e179.
Harms, M., Benitez, B.A., Cairns, N., Cooper, B., Cooper, P., Mayo, K., Carrell, D.,
Faber, K., Williamson, J., Bird, T., Diaz-Arrastia, R., Foroud, T.M., Boeve, B.F., Graff-
Radford, N.R., Mayeux, R., Chakraverty, S., Goate, A.M., Cruchaga, C., NIA-LOAD/
NCRAD Family Study Consortium, 2013. C9orf72 hexanucleotide repeat expan-
sions in clinical Alzheimer disease. JAMA Neurol. 70, 736e741.
He, J., Tang, L., Benyamin, B., Shah, S., Hemani, G., Liu, R., Ye, S., Liu, X., Ma, Y.,
Zhang, H., Cremin, K., Leo, P., Wray, N.R., Visscher, P.M., Xu, H., Brown, M.A.,
Bartlett, P.F., Mangelsdorf, M., Fan, D., 2015. C9orf72 hexanucleotide repeat
expansions in Chinese sporadic amyotrophic lateral sclerosis. Neurobiol. Aging.
36, 2660.e1e2660.e8.
Jiao, B., Guo, J.F., Wang, Y.Q., Yan, X.X., Zhou, L., Liu, X.Y., Zhang, F.F., Zhou, Y.F., Xia, K.,
Tang, B.S., Shen, L., 2013. C9orf72 mutation is rare in Alzheimer’s disease, Par-
kinson’s disease, and essential tremor in China. Front. Cell. Neurosci. 7, 164.
Kaivola, K., Jansson, L., Saarentaus, E., Kiviharju, A., Rantalainen, V., Eriksson, J.G.,
Strandberg, T.E., Polvikoski, T., Myllykangas, L., Tienari, P.J., 2018. Heterozygous
TYROBP deletion (PLOSLFIN) is not a strong risk factor for cognitive impairment.
Neurobiol. Aging. 64, 159.e1e159.e4.
Kajantie, E., Pietilainen, K.H., Wehkalampi, K., Kananen, L., Raikkonen, K.,
Rissanen, A., Hovi, P., Kaprio, J., Andersson, S., Eriksson, J.G., Hovatta, I., 2012. No
association between body size at birth and leucocyte telomere length in adult
life–evidence from three cohort studies. Int. J. Epidemiol. 41, 1400e1408.
Kohli, M.A., John-Williams, K., Rajbhandary, R., Naj, A., Whitehead, P., Hamilton, K.,
Carney, R.M., Wright, C., Crocco, E., Gwirtzman, H.E., Lang, R., Beecham, G.,
Martin, E.R., Gilbert, J., Benatar, M., Small, G.W., Mash, D., Byrd, G., Haines, J.L.,
Pericak-Vance, M.A., Zuchner, S., 2013. Repeat expansions in the C9ORF72 gene
contribute to Alzheimer’s disease in Caucasians. Neurobiol. Aging. 34,
1519.e5e1519.e12.
Lahti, M., Eriksson, J.G., Heinonen, K., Kajantie, E., Lahti, J., Wahlbeck, K.,
Tuovinen, S., Pesonen, A.K., Mikkonen, M., Osmond, C., Raikkonen, K., 2014.
Maternal Grand multiparity and the risk of severe mental disorders in adult
offspring. PLoS One 9, e114679.
Majounie, E., Renton, A.E., Mok, K., Dopper, E.G., Waite, A., Rollinson, S., Chio, A.,
Restagno, G., Nicolaou, N., Simon-Sanchez, J., van Swieten, J.C., Abramzon, Y.,
Johnson, J.O., Sendtner, M., Pamphlett, R., Orrell, R.W., Mead, S., Sidle, K.C.,
Houlden, H., Rohrer, J.D., Morrison, K.E., Pall, H., Talbot, K., Ansorge, O., ,
K. Kaivola et al. / Neurobiology of Aging 84 (2019) 242.e7e242.e12 242.e12Chromosome 9-ALS/FTD Consortium, French research network on FTLD/FTLD/
ALS, ITALSGEN Consortium, Hernandez, D.G., Arepalli, S., Sabatelli, M., Mora, G.,
Corbo, M., Giannini, F., Calvo, A., Englund, E., Borghero, G., Floris, G.L.,
Remes, A.M., Laaksovirta, H., McCluskey, L., Trojanowski, J.Q., Van Deerlin, V.M.,
Schellenberg, G.D., Nalls, M.A., Drory, V.E., Lu, C.S., Yeh, T.H., Ishiura, H.,
Takahashi, Y., Tsuji, S., Le Ber, I., Brice, A., Drepper, C., Williams, N., Kirby, J.,
Shaw, P., Hardy, J., Tienari, P.J., Heutink, P., Morris, H.R., Pickering-Brown, S.,
Traynor, B.J., 2012. Frequency of the C9orf72 hexanucleotide repeat expansion in
patients with amyotrophic lateral sclerosis and frontotemporal dementia: a
cross-sectional study. Lancet Neurol. 11, 323e330.
Martorell, L., Gamez, J., Cayuela, M.L., Gould, F.K., McAbney, J.P., Ashizawa, T.,
Monckton, D.G., Baiget, M., 2004. Germline mutational dynamics in myotonic
dystrophy type 1 males: allele length and age effects. Neurology 62, 269e274.
McGoldrick, P., Zhang, M., van Blitterswijk, M., Sato, C., Moreno, D., Xiao, S.,
Zhang, A.B., McKeever, P.M., Weichert, A., Schneider, R., Keith, J., Petrucelli, L.,
Rademakers, R., Zinman, L., Robertson, J., Rogaeva, E., 2018. Unaffected mosaic
C9orf72 case: RNA foci, dipeptide proteins, but upregulated C9orf72 expression.
Neurology 90, e323ee331.
Murphy, N.A., Arthur, K.C., Tienari, P.J., Houlden, H., Chio, A., Traynor, B.J., 2017. Age-
related penetrance of the C9orf72 repeat expansion. Sci. Rep. 7, 2116.
Myers, R.H., MacDonald, M.E., Koroshetz, W.J., Duyao, M.P., Ambrose, C.M.,
Taylor, S.A., Barnes, G., Srinidhi, J., Lin, C.S., Whaley, W.L., 1993. De novo
expansion of a (CAG)n repeat in sporadic Huntington’s disease. Nat. Genet. 5,
168e173.
Myllykangas, L., Polvikoski, T., Sulkava, R., Verkkoniemi, A., Crook, R., Tienari, P.J.,
Pusa, A.K., Niinisto, L., O’Brien, P., Kontula, K., Hardy, J., Haltia, M., Perez-Tur, J.,
1999. Genetic association of alpha2-macroglobulin with Alzheimer’s disease in
a Finnish elderly population. Ann. Neurol. 46, 382e390.
Ng, A.S.L., Tan, E.K., 2017. Intermediate C9orf72 alleles in neurological disorders:
does size really matter? J. Med. Genet. 54, 591e597.
Nuytemans, K., Bademci,G., Kohli,M.M., Beecham,G.W.,Wang, L., Young, J.I., Nahab, F.,
Martin, E.R., Gilbert, J.R., Benatar, M., Haines, J.L., Scott, W.K., Zuchner, S., Pericak-
Vance, M.A., Vance, J.M., 2013. C9ORF72 intermediate repeat copies are a signif-
icant risk factor for Parkinson disease. Ann. Hum. Genet. 77, 351e363.
Purcell, S., Cherny, S.S., Sham, P.C., 2003. Genetic Power Calculator: design of linkage
and association genetic mapping studies of complex traits. Bioinformatics 19,
149e150.
Rahkonen, T., Eloniemi-Sulkava, U., Rissanen, S., Vatanen, A., Viramo, P., Sulkava, R.,
2003. Dementia with Lewy bodies according to the consensus criteria in a
general population aged 75 years or older. J. Neurol. Neurosurg. Psychiatry. 74,
720e724.
Renton, A.E., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, J.R.,
Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L., Kalimo, H.,
Paetau, A., Abramzon, Y., Remes, A.M., Kaganovich, A., Scholz, S.W.,
Duckworth, J., Ding, J., Harmer, D.W., Hernandez, D.G., Johnson, J.O., Mok, K.,
Ryten, M., Trabzuni, D., Guerreiro, R.J., Orrell, R.W., Neal, J., Murray, A.,
Pearson, J., Jansen, I.E., Sondervan, D., Seelaar, H., Blake, D., Young, K.,
Halliwell, N., Callister, J.B., Toulson, G., Richardson, A., Gerhard, A., Snowden, J.,
Mann, D., Neary, D., Nalls, M.A., Peuralinna, T., Jansson, L., Isoviita, V.M.,
Kaivorinne, A.L., Holtta-Vuori, M., Ikonen, E., Sulkava, R., Benatar, M., Wuu, J.,
Chio, A., Restagno, G., Borghero, G., Sabatelli, M., ITALSGEN Consortium,
Heckerman, D., Rogaeva, E., Zinman, L., Rothstein, J.D., Sendtner, M., Drepper, C.,
Eichler, E.E., Alkan, C., Abdullaev, Z., Pack, S.D., Dutra, A., Pak, E., Hardy, J.,
Singleton, A., Williams, N.M., Heutink, P., Pickering-Brown, S., Morris, H.R.,
Tienari, P.J., Traynor, B.J., 2011. A hexanucleotide repeat expansion in C9ORF72 is
the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257e268.
Rutherford, N.J., Heckman, M.G., Dejesus-Hernandez, M., Baker, M.C., Soto-
Ortolaza, A.I., Rayaprolu, S., Stewart, H., Finger, E., Volkening, K., Seeley, W.W.,
Hatanpaa, K.J., Lomen-Hoerth, C., Kertesz, A., Bigio, E.H., Lippa, C.,
Knopman, D.S., Kretzschmar, H.A., Neumann, M., Caselli, R.J., White 3rd, C.L.,
Mackenzie, I.R., Petersen, R.C., Strong, M.J., Miller, B.L., Boeve, B.F., Uitti, R.J.,
Boylan, K.B., Wszolek, Z.K., Graff-Radford, N.R., Dickson, D.W., Ross, O.A.,
Rademakers, R., 2012. Length of normal alleles of C9ORF72 GGGGCC repeat do
not inﬂuence disease phenotype. Neurobiol. Aging. 33, 2950.e5e2950.e7.
Solomon, A., Ngandu, T., Soininen, H., Hallikainen, M.M., Kivipelto, M.,
Laatikainen, T., 2014. Validity of dementia and Alzheimer’s disease diagnoses in
Finnish national registers. Alzheimers Dement. 10, 303e309.
Strandberg, T.E., Salomaa, V., Strandberg, A.Y., Vanhanen, H., Sarna, S., Pitkala, K.,
Rantanen, K., Savela, S., Pienimaki, T., Huohvanainen, E., Stenholm, S.,
Raikkonen, K., Tilvis, R.S., Tienari, P.J., Huttunen, J., 2016. Cohort proﬁle: the
Helsinki businessmen study (HBS). Int. J. Epidemiol. 45, 1074, 1074h.Tanskanen, M., Makela, M., Notkola, I.L., Myllykangas, L., Rastas, S., Oinas, M.,
Lindsberg, P.J., Polvikoski, T., Tienari, P.J., Paetau, A., 2017. Population-based
analysis of pathological correlates of dementia in the oldest old. Ann. Clin.
Transl. Neurol. 4, 154e165.
Theuns, J., Verstraeten, A., Sleegers, K., Wauters, E., Gijselinck, I., Smolders, S.,
Crosiers, D., Corsmit, E., Elinck, E., Sharma, M., Kruger, R., Lesage, S., Brice, A.,
Chung, S.J., Kim, M.J., Kim, Y.J., Ross, O.A., Wszolek, Z.K., Rogaeva, E., Xi, Z.,
Lang, A.E., Klein, C., Weissbach, A., Mellick, G.D., Silburn, P.A.,
Hadjigeorgiou, G.M., Dardiotis, E., Hattori, N., Ogaki, K., Tan, E.K., Zhao, Y.,
Aasly, J., Valente, E.M., Petrucci, S., Annesi, G., Quattrone, A., Ferrarese, C.,
Brighina, L., Deutschlander, A., Puschmann, A., Nilsson, C., Garraux, G.,
LeDoux, M.S., Pfeiffer, R.F., Boczarska-Jedynak, M., Opala, G., Maraganore, D.M.,
Engelborghs, S., De Deyn, P.P., Cras, P., Cruts, M., Van Broeckhoven, C., GEO-PD
Consortium, 2014. Global investigation and meta-analysis of the C9orf72 (G4C2)
n repeat in Parkinson disease. Neurology 83, 1906e1913.
Uusvaara, J., Pitkala, K.H., Kautiainen, H., Tilvis, R.S., Strandberg, T.E., 2013. Detailed
cognitive function and use of drugs with anticholinergic properties in older
people: a community-based cross-sectional study. Drugs Aging 30, 177e182.
van der Zee, J., Gijselinck, I., Dillen, L., Van Langenhove, T., Theuns, J., Engelborghs, S.,
Philtjens, S., Vandenbulcke, M., Sleegers, K., Sieben, A., Baumer, V., Maes, G.,
Corsmit, E., Borroni, B., Padovani, A., Archetti, S., Perneczky, R., Diehl-Schmid, J.,
de Mendonca, A., Miltenberger-Miltenyi, G., Pereira, S., Pimentel, J., Nacmias, B.,
Bagnoli, S., Sorbi, S., Graff, C., Chiang, H.H., Westerlund, M., Sanchez-Valle, R.,
Llado, A., Gelpi, E., Santana, I., Almeida, M.R., Santiago, B., Frisoni, G., Zanetti, O.,
Bonvicini, C., Synofzik, M., Maetzler, W., Vom Hagen, J.M., Schols, L.,
Heneka, M.T., Jessen, F., Matej, R., Parobkova, E., Kovacs, G.G., Strobel, T.,
Sarafov, S., Tournev, I., Jordanova, A., Danek, A., Arzberger, T., Fabrizi, G.M.,
Testi, S., Salmon, E., Santens, P., Martin, J.J., Cras, P., Vandenberghe, R., De
Deyn, P.P., Cruts, M., Van Broeckhoven, C., van der Zee, J., Gijselinck, I., Dillen, L.,
Van Langenhove, T., Theuns, J., Philtjens, S., Sleegers, K., Baumer, V., Maes, G.,
Corsmit, E., Cruts, M., Van Broeckhoven, C., van der Zee, J., Gijselinck, I., Dillen, L.,
Van Langenhove, T., Philtjens, S., Theuns, J., Sleegers, K., Baumer, V., Maes, G.,
Cruts, M., Van Broeckhoven, C., Engelborghs, S., De Deyn, P.P., Cras, P.,
Engelborghs, S., De Deyn, P.P., Vandenbulcke, M., Vandenbulcke, M., Borroni, B.,
Padovani, A., Archetti, S., Perneczky, R., Diehl-Schmid, J., Synofzik, M.,
Maetzler, W., Muller Vom Hagen, J., Schols, L., Synofzik, M., Maetzler, W., Muller
Vom Hagen, J., Schols, L., Heneka, M.T., Jessen, F., Ramirez, A., Kurzwelly, D.,
Sachtleben, C., Mairer, W., de Mendonca, A., Miltenberger-Miltenyi, G.,
Pereira, S., Firmo, C., Pimentel, J., Sanchez-Valle, R., Llado, A., Antonell, A.,
Molinuevo, J., Gelpi, E., Graff, C., Chiang, H.H., Westerlund, M., Graff, C., Kinhult
Stahlbom, A., Thonberg, H., Nennesmo, I., Borjesson-Hanson, A., Nacmias, B.,
Bagnoli, S., Sorbi, S., Bessi, V., Piaceri, I., Santana, I., Santiago, B., Santana, I.,
Helena Ribeiro, M., Rosario Almeida, M., Oliveira, C., Massano, J., Garret, C.,
Pires, P., Frisoni, G., Zanetti, O., Bonvicini, C., Sarafov, S., Tournev, I., Jordanova, A.,
Tournev, I., Kovacs, G.G., Strobel, T., Heneka, M.T., Jessen, F., Ramirez, A.,
Kurzwelly, D., Sachtleben, C., Mairer, W., Jessen, F., Matej, R., Parobkova, E.,
Danel, A., Arzberger, T., Maria Fabrizi, G., Testi, S., Ferrari, S., Cavallaro, T.,
Salmon, E., Santens, P., Cras, P., European Early-Onset Dementia Consortium,
2013. A pan-European study of the C9orf72 repeat associated with FTLD:
geographic prevalence, genomic instability, and intermediate repeats. Hum.
Mutat. 34, 363e373.
Wheeler, V.C., Auerbach, W., White, J.K., Srinidhi, J., Auerbach, A., Ryan, A.,
Duyao, M.P., Vrbanac, V., Weaver, M., Gusella, J.F., Joyner, A.L., MacDonald, M.E.,
1999. Length-dependent gametic CAG repeat instability in the Huntington’s
disease knock-in mouse. Hum. Mol. Genet. 8, 115e122.
Xi, Z., Zinman, L., Grinberg, Y., Moreno, D., Sato, C., Bilbao, J.M., Ghani, M.,
Hernandez, I., Ruiz, A., Boada, M., Moron, F.J., Lang, A.E., Marras, C., Bruni, A.,
Colao, R., Maletta, R.G., Puccio, G., Rainero, I., Pinessi, L., Galimberti, D.,
Morrison, K.E., Moorby, C., Stockton, J.D., Masellis, M., Black, S.E., Hazrati, L.N.,
Liang, Y., van Haersma de With, J., Fornazzari, L., Villagra, R., Rojas-Garcia, R.,
Clarimon, J., Mayeux, R., Robertson, J., St George-Hyslop, P., Rogaeva, E., 2012.
Investigation of c9orf72 in 4 neurodegenerative disorders. Arch. Neurol. 69,
1583e1590.
Yliharsila, H., Kajantie, E., Osmond, C., Forsen, T., Barker, D.J., Eriksson, J.G., 2007.
Birth size, adult body composition and muscle strength in later life. Int. J. Obes.
(Lond). 31, 1392e1399.
Zhang, K., Donnelly, C.J., Haeusler, A.R., Grima, J.C., Machamer, J.B., Steinwald, P.,
Daley, E.L., Miller, S.J., Cunningham, K.M., Vidensky, S., Gupta, S., Thomas, M.A.,
Hong, I., Chiu, S.L., Huganir, R.L., Ostrow, L.W., Matunis, M.J., Wang, J., Sattler, R.,
Lloyd, T.E., Rothstein, J.D., 2015. The C9orf72 repeat expansion disrupts nucle-
ocytoplasmic transport. Nature 525, 56e61.
